However, non-specific COX2 inhibitor such as Aspirin and non-steroidal anti-inflammatory drugs (NSAID) are frequently administrated to cancer patients receiving ICB and retrospective analyses provided contradictory results making impossible to conclude if COX2 inhibition would be or not beneficial in combination with ICB at least for lung cancer (81, 82). This evidence concerns the gene PTGS2 and lung carcinoma.